Pharmacogenetic Dosing of Warfarin

Purpose:

Warfarin is now the most commonly used oral anticoagulant. This drug has inter-individual variability due to the genetic polymorphisms in the warfarin metabolizing enzyme, CYP2C9 and warfarin target, VKORC1. The investigators' team developed a pharmacogenetic dosing algorithm which can predict patients required warfarin dose, thus could prevent warfarin induced warfarin adverse events.

Methods:

The investigators recruited patients with indications for warfarin, the genotypes of VKORC1 and CYP2C9 were determined by the hospitals and verified by National Center for Genome Medicine. The investigators then randomized the patients to one of three arms: 1. Warfarin dose predicted by dosing algorithm developed by the International Warfarin pharmacogenetic Consortium (IWPC), 2. Algorithm developed by the Taiwan Warfarin Consortium and 3. Standard of care. The investigators aimed to determine whether using genetic dosing algorithm can lead to more stable dose and safer use of the drug.

Study Overview

• Status: Completed
• Conditions: Stroke; Venous Thrombosis; Atrial Fibrillation; Atrial Flutter
• Intervention / Treatment: Behavioral: Standard of care dosing for warfarin; Genetic: Genotype-guided dosingTaiwan algorithm for warfarin; Genetic: Genotype-guided dosing IWPC algorithm for warfarin

• Study Type: Interventional
• Enrollment (Actual): 300
• Phase: Phase 3

Contacts and Locations

Study Locations

• Taiwan
  • Kaohsiung, Taiwan, 807
    • Kaohsiung Medical University
  • Taichung, Taiwan, 404
    • China Medical University Hospital
  • Taoyuan, Taiwan, 333
    • Chang Gung Memorial Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients must give their informed consent and complete the case report form.
• Patients must be over the age of 20.
• Patients have clinical indications for warfarin therapy but do not have any prior warfarin treatment.

Exclusion Criteria:

• Patients who did not complete the informed consent form or the CRF
• Patients who are less than the age of 20.
• Patients who had prior or is currently on warfarin treatment.
• Patients who have hemorrhagic tendencies or hemorrhagic diseases defined as copious bleeding caused by viral or bacterial infections; cancer and hepatic dysfunction defined as GOP and GPT values three times higher than normal value
• Patients who has Vitamin K deficiency
• Female patients who is currently pregnant

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Standard of care dosing for warfarin; Loading dose (5mg) of warfarin for the first 3 days of treatment. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).	Behavioral: Standard of care dosing for warfarin
Experimental: Genotype-guided dosingTaiwan algorithm for warfarin; Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the Taiwan algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).	Genetic: Genotype-guided dosingTaiwan algorithm for warfarin
Experimental: Genotype-guided dosing IWPC algorithm for warfarin; Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the IWPC algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).	Genetic: Genotype-guided dosing IWPC algorithm for warfarin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time spent in target INR range	time spent in target INR range Time in the target INR Range will be the primary endpoints because of its strong association with adverse events: patients with subtherapeutic INR values are at increased risk of thrombosis and patients with high INR values are at increased risk of hemorrhage during warfarin treatment initiation.	first month of therapy

Collaborators and Investigators

• Sponsor: Academia Sinica, Taiwan
• Collaborators: China Medical University Hospital; Chang Gung Memorial Hospital; Kaohsiung Medical University
• Investigators: Principal Investigator: Ming Ta Michael Lee, PhD, Institute of Biomedical Sciences, Academia Sinica

Publications and helpful links

General Publications

• Ohara M, Takahashi H, Lee MT, Wen MS, Lee TH, Chuang HP, Luo CH, Arima A, Onozuka A, Nagai R, Shiomi M, Mihara K, Morita T, Chen YT. Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses. PLoS One. 2014 Aug 22;9(8):e105891. doi: 10.1371/journal.pone.0105891. eCollection 2014.

Study record dates

Study Major Dates

• Study Start: September 1, 2009
• Primary Completion (Actual): December 1, 2013
• Study Completion (Actual): December 1, 2013

Study Registration Dates

• First Submitted: February 9, 2014
• First Submitted That Met QC Criteria: February 16, 2014
• First Posted (Estimate): February 19, 2014

Study Record Updates

• Last Update Posted (Estimate): February 19, 2014
• Last Update Submitted That Met QC Criteria: February 16, 2014
• Last Verified: February 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Embolism and Thrombosis; Arrhythmias, Cardiac; Atrial Fibrillation; Thrombosis; Venous Thrombosis; Atrial Flutter; Anticoagulants; Warfarin
• Other Study ID Numbers: AS-IRB01-100070